CD4 and neoplasm: Taking advantage of immunocompetent transgenic mouse HNSCC models, we observed a decrease in MDSCs, TAMs, and mature DCs as well as an increase in CD8+ T cells and CD4+ T cells by PD-1 blockade in micro- and macro- tumor environment.